#1ResMed Corporate & Investor Presentation Updated: August 5, 2020#2Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com). In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, tax outlook, and the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology. ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements. 2 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#3Company Overview & Strategy ResMed#4Who we are / what we do • ● ● Listed on NYSE & ASX, ~$29B market cap World-leading digital health company with over 12 million 100% cloud-connectable devices - ~14 million patients in AirView monitoring ecosystem - More than 95 million patient accounts in out-of-hospital care network Innovative designer and manufacturer of award-winning devices and cloud-based software solutions . - – Diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions Products and solutions designed to improve patient quality of life, reduce impact of chronic disease, and lower healthcare costs Cloud-based software solutions and devices designed to provide connected care, improving patient outcomes and efficiencies for healthcare providers - Tools that allow fewer people to manage more patients - Empower patients to track own health outcomes 4 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Med my Air Au 85 1:00 points Excellent resultsex A ResMed#5Why invest? - driving long-term shareholder value Market Dynamics Growth & Innovation Financial Results • Underpenetrated markets in sleep and COPD • Healthcare costs continue to increase • Focus on improving patient outcomes • Value-based technology solutions • Global leader in digital health for sleep and respiratory care • Long-term growth opportunities •6,000+ patents and designs •~7-8% of revenue invested in R&D • Historical revenue and profit growth . • Recurring revenue • Operating excellence program • Strong track record of disciplined capital deployment Total Shareholder Return (NYSE shares as of 6/30/2020): 1-yr 59% 3-yr 157% ☐ 5-yr 270% 5 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#6ResMed 2025: a patient-centric, digitally-enabled strategy Expect impact of COVID-19 will accelerate this strategy ResMed 250 million lives improved in out-of-hospital healthcare 2025 in 2025! Purpose⚫ Empower people to live happier, healthier and higher quality lives in the comfort of their home Growth Focus Global health epidemics in sleep apnea, COPD, other major chronic conditions, and SaaS solutions that improve care in out-of-hospital settings Growth Advantage Transform care through innovative solutions and tech-driven integrated care to drive superior outcomes, experiences and efficiency Growth Foundations⚫ High-performing, diverse and entrepreneurial people Industry-leading innovation and business excellence Digital health technology and scientific leadership 6 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 N ResMed#7Our Business: Sleep ResMed#8Sleep business strategy Deliver a world-class patient experience through innovative solutions that lower overall costs for treating sleep apnea patients and improve clinical outcomes OPTIMIZE EFFICIENCIES FOR PROVIDERS Home medical equipment / home care provider-facing solutions that drive workflow efficiencies Long-term adherence solutions that . improve patient management and meet the needs of referring physicians DELIVER BEST-IN- CLASS PATIENT EXPERIENCE Patient-facing solutions, from identification to treatment, that streamline the experience and improve long-term adherence EMBRACE AND ENABLE INTEGRATED CARE MODELS Payer-facing solutions that enable population management, backed by our data insights, outcomes research, and market access Collaboration – Operating Excellence – Lean Innovation – High Performance Culture – Talent 8 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#9What is sleep-disordered breathing? Abnormal respiration during sleep - the cessation of breathing or "sleep suffocation" Most prevalent is obstructive sleep apnea - collapse of the upper airway despite ongoing effort Other types include central sleep apnea - lack of breathing and lack of effort - and mixed apnea Normal airway Partially obstructed airway Obstructed airway Arousal 9 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#10Sleep apnea is more than 80% undiagnosed... ....and is highly prevalent in other chronic conditions For every 100 U.S. adults... Stroke3 72% 4 KNOW THEY HAVE SLEEP APNEA¹2 E•E•E ர்ர் 1 Peppard PE et al. Am J Epidemiol 2013 2 Young T et al. Sleep 1997 •E •E •E•E•E 22 DON'T KNOW THEY HAVE IT¹.2 10 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Type 2 Diabetes4 72% Obesity5 77% Atrial Fibrillation6 74% Heart Failure? 76% Drug-Resistant Hypertension³ 83% 3 Johnson KG and Johnson DC. J Clin Sleep Med 2010 4 Einhorn D et al. Endocr Pract 2007 6 Bitter T et al. Dtsch Arztebl Int. 2009 7 Oldenburg O et al. Eur J Heart Fail 2007 5 O'Keeffe T and Patterson EJ. Obes Surg 2004 8 Logan AG et al. J Hypertens 2001 ResMed#11The global prevalence of sleep apnea is enormous and growing... United States =1 AHI≥5 = 54 M AHI≥15 24 M Brazil AHI≥549 M AHI≥15 = 25 M =1 Benjafield AV et al. Lancet Respir Med 2019 11 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 France AHI≥5 = 24 M AHI≥15 12 M = Germany AHI≥5 = 26 M AHI≥1514 M China AHI≥5 Nigeria AHI≥5 = 31 M AHI≥1512 M 176 M AHI≥15 = 66 M Pakistan AHI≥5 = 42 M AHI≥15 17 M India AHI≥5 = 52 M AHI≥15 29 M = AHI ≥ 5 936,360,689 AHI ≥ 15 424,630,028 Russian Federation AHI≥5 = 40 M AHI≥15 20 M Japan AHI≥5 22 M = AHI≥15 9 M ResMed#12Our partnerships will address sleep health as a public health crisis Sleep research joint venture with Verily Develop software solutions to help identify, diagnose, treat, and manage those with OSA • To study the health and financial impacts of untreated sleep apnea - Prove the ROI for treating OSA Identify, engage, enroll Expand the funnel & verily ResMed 12 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 100 600 Jul With Verily, we can unlock richer, more holistic insights about sleep apnea and the value of treating it ResMed#13Reducing mortality with PAP therapy U.S. multicenter, population-based cohort study Study included 392 patients with sleep apnea, with 11 years of follow-up •Positive airway pressure therapy associated with a 62% lower risk of all-cause mortality • Death rate was twice as high for persons who did not receive positive airway pressure therapy - (24.7 vs 12.8 deaths per 1000 person years, p = 0.03) Lisan Q et al. JAMA Otolaryngol Head Neck Surg 2019 13 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 100 Proportion Surviving, % 70- 80 80 90 60 0 Sleep Heart Health Study HR, 0.38 (95% CI, 0.18-0.81) PAP prescribed PAP not prescribed 5 10 15 20 Time, y ResMed#14Demonstrated positive dose-response relationship between increased CPAP usage and lower healthcare costs For every one hour per night increase in PAP usage there was an 8% decrease in inpatient visits and a 4% decrease in overall acute care visits.1 8% Each Hour 4% PAP Usage 1. Kirsch DB et al. J Clin Sleep Med 2019 * Overall visits" includes inpatient, ED, and observation visits. 14 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Inpatient Visits Overall Visits* ResMed#15Study demonstrates the effectiveness of CPAP therapy and quality of life improvements for those with mild obstructive sleep apnea MERGE trial: clinical effectiveness of CPAP treatment in patients with mild obstructive sleep apnea Demonstrated improvement in 56. ● CPAP -Standard care Quality of Life (SF-36 vitality scale) Treatment effect 7-5 (95% CI 5-3-9-6); p<0-0001 54- for CPAP patients vs. standard • care • Symptomatic benefits: • Reductions in sleepiness 52 Mean vitality score (95% CI) 46- 48- g Improvements in fatigue and depression Compelling evidence supports the need and benefits of treating mild OSA Combined with recently published global prevalence research, 936M patients worldwide can benefit from PAP treatment 44 42- T 40 Baseline Month 3 Visit Change in SF-36 Vitality Scale in Patients with Mild OSA per AASM 2012 Wimms et al. Lancet Respir Med 2019 15 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 MMERGE Blackpool Liverpool Cambridge Oxford Taunton Dundee Plymouth UK Respiratory Sleep Research Network Newcastle Stevenage London (G&ST) London (RB&HT) ResMed#16Transforming the treatment & management of sleep apnea 唱 Quiet 品 Compact AirMini™ 90 16 界 AirSense™ 10 AirSense™ 10 AUTOSET FOR HER Minimalist Small. Light. Simple. Comfortable AirFit™ F30 AirFit™ N30 AirFit P10 Full face mask Nasal Pillows System AirFit™ F30i Freedom Sleep in any position. AirFit N30 Nasal cradle mask AirFit™ P30i Nasal pillows mask © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 AirCurve™ 10 Ultra Soft Patented memory foam offers unique comfort. AirTouch F20 ill face mask Universal Fit Classic designs that fit nearly every face. AirFit™ F20 AirFit™ N20 Full face mask Nasal mask RosMed Connected brightree by ResMed 85 85 AirView™ Cloud-based patient management system myAir TM Patient engagement program ResMed#17Our Business: Respiratory Care ResMed#18Respiratory care strategy Changing the lives of COPD patients by bringing new solutions for unmet patient needs • WIN IN THE CORE Reach more COPD patients through connected non-invasive ventilation Drive profitable growth in life-support ventilation Grow POC sales through business model innovation • INNOVATE AND EXPAND INTO ADJACENCIES Treat patients earlier in COPD disease progression through a connected ecosystem Continue to leverage investments in life support and NIV Further innovate & scale the portable oxygen business model Better prove connected health value propositions TRANSFORM COPD HEALTHCARE DELIVERY Build intelligent therapy solutions enabled by sensor technologies, data analytics, Al and ML with improved patient/care giver engagement Create value propositions in longitudinal care, predict exacerbations, and prevent hospitalization Support new business models & tailored products in emerging growth markets - Collaboration – Operating Excellence – Lean Innovation – High Performance Culture - Talent 18 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#19What is chronic obstructive pulmonary disease (COPD)? COPD is a serious lung disease that over time, makes it hard to breathe Causes include: Smoking, vaping, & secondhand smoke Pollution Occupational exposure to noxious gases . A history of childhood infections (could be a catalyst) Genetic inheritance, leading to its onset 19 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 O 000 000 9 O O 0 O 0 O D 9 ResMed#20COPD is a large and growing market + More than 380 million people worldwide are estimated to have COPD - Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil and E. Europe may be well over 100 million $ Cost to healthcare systems from COPD is enormous: + - Europe: ~48 billion per year – United States: ~$50 billion per year - More than 3 million people worldwide die each year due to COPD 1. Adeloye D et al. J Glob Health 2015 2. ERS White Book. https://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/ 3. NHLBI. Morbidity & Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases 4. WHO 2017 https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) 20 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#21There is a need for end-to-end solutions for COPD patients Global population of COPD patients: ~380 million¹ Self-management (smoking cessation, diet, exercise) Inhaled Pharmaceuticals for COPD 75% of pop. Stage II Increasing severity of disease COPD progression Stage I 21 - updated © 2020 ResMed | Corporate & Investor Presentation Adele Det Glob Health 2015 Oxygen Ventilation 20% of pop. <1% of pop. Stage III Stage IV ResMed#22Our digital health platform supports COPD patients on their healthcare journey The digital respiratory Integrated Care Model we are creating through Propeller Data processed by a powerful insights engine Spirometry Connected medicines Non-invasive ventilation Q Pulse oximetry 89 >>> Oxygen concentrator O2 Environment (Indoor/outdoor) Patient-reported outcomes zzz Activity/sleep The Integrated Care Model will support patients through their chronic respiratory disease journey 22 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Artificial Intelligence Driving value propositions for stakeholders 02 Order telehealth consultation Exacerbation alert Clinician decision support (e.g., recommend POC) Pollen alert Clinical data for patients/clinicians Machine Learning - Recommend rehab Order test ResMed#23We have the full spectrum of solutions for respiratory care Patient Management ResMed ArView Ventilation patients+ Location palalai 000- Page, Jimmy Look LANK CLO Foujones, jah AHR D0/171954 Devin 150, Back P nem con My pollo Adration From -204-8150 F-435 Pattanaya Pacitate what Sanct Exaunde: 4houre for 2 drys Jople Ji 1:4 hear 00000 0000-000 cheap look Daverts Water Fedor 10-01-COM) AirView™ for Respiratory Bilevel Ventilation AirCurve 10™ Digital Therapeutics COPD Assessment Test chahow your cordha As Daily Schedale Stal Propeller 2000 Non-invasive Ventilation (NIV) Feed Lumis™ Stellar™ Patient Acuity 23 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Portable Oxygen High-Flow Therapy Mobi™ AcuCare™ high flow Life Support Ventilation Pisnere Astral T TM Astral™ with RCM ResMed#24Our Business: Software as a Service (SaaS) ResMed#25SaaS portfolio well positioned to improve outcomes and lower costs across out-of-hospital healthcare Better patient experience. Improved clinical outcomes. Lower overall cost of care. Intelligent workflow Privacy • Security Advanced analytics Interoperability Single view of the patient • Comprehensive interoperability • Care transition, coordination, and collaboration Seamless access to information for patients and those who care for them Manage populations across provider / care settings Data insights to enable better care / better results Connected systems deliver the best outcomes for value-based care 25 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#26Leading provider of cloud-based software for out-of-hospital care providers across multiple settings Loved One/ Caregiver Physician MatrixCare by ResMed Skilled Nursing Home Health brightree by ResMed ResMed છે 09 Patients and Residents $$ Payor Private Duty Senior Living Hospice MatrixCare HEALTHCARE first HEALTHCARE first by ResMed by ResMed brightree by ResMed brightree by ResMed 26 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Brightree HME Providers ResMed Sleep and RC Products & Solutions Life Plan Community Hospital ResMed#27SaaS portfolio is operating at scale and creating value Portfolio is financially attractive on its own and with leading positions in key segments. $ 27 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Supports growth for existing businesses (HME) and chronic diseases, sleep apnea and COPD in particular. Breadth and scale creates our competitive advantage. ResMed#28Digital Health Technology ResMed#29Digital health technology is our foundation Purpose: Enable all ResMed businesses to achieve their business objectives by leveraging technology, data, and advanced analytics. Sleep Respiratory Care SaaS 用 ↑ ↑ ↑ ↑ ↑ ↑ ↑↑ Digital Health Technology Technology 22 Advanced Analytics 29 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#30Our digital health solutions improve outcomes and lower costs TM myAir APPS/DIGITAL THERAPEUTICS DEVICES ResMed Ecosystem Connected Devices and Digital Health Propeller Out-of-Hospital Platform CLINICIAN PATIENT/ CONSUMER AirView™ IDN HME/PAYORS 30 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 brightree by ResMed Artificial Intelligence MatrixCare by ResMed Machine Learning HEALTHCARE first by ResMed 1 Patient Outcomes -0-0- Business Outcomes Operations ResMed#31We transform 6.5+ billion nights of medical data into useful outcomes End-to-end digital health solutions in sleep, respiratory care, and out-of-hospital healthcare ApneaLink Air Type Ill home sleep testing device T 31 ResMed ApneaLink Air DIAGNOSIS TH AirView DIAGNOSTICS Air10™ series AirView™ AirView™ ActionGroups MyAir 12 34 Cor: b 01011 Ongping alu 05 Astral™ with RCM - 10 THERAPY AirMini™ ResMed © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 90 ww 10 78 Hatake red 11 B 10 brightree. MONITORING & MGMT. PATIENT ENGAGEMENT BILLING & INTEGRATIONS Go Scripts ReSupply Propeller Compele eienaar Damer Se ResMed Data Exchange 3rd Party Integrations I ResMed#32Global leader in digital health AirView™ has nearly 14 million patients 1 million+ diagnostic tests processed in the cloud ~100 API calls per second from integrators >12 million 100% cloud connectable devices worldwide 95+ million accounts in out-of-hospital care network 2.5 million+ patients have signed up for myAir' TM 32 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#33Recent Quarterly Results ResMed#34Our response to COVID-19: Focused on preservation of life Our ResMed Team Work-from-home policy for all employees when job can be performed remotely Specific actions to protect and support employees working in our manufacturing and distribution sites, including: - - - split shifts (A/B/C) increased cleaning, personal hygiene, and safety protocols including temperature checks - personal protective equipment for all staff (PPE) Increased cadence of communications and engagement with employees Our Stakeholders Fair and ethical allocation of products globally supported by an epidemiological model Transitioned manufacturing lines to support production of ventilation products to meet global demand - - Tripled manufacturing of ventilators Scaled up ventilation mask production more than 10x • Updated and ongoing clinical information 34 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Increased digital health technology and remote patient care services for customers . . Business Continuity Established key workstreams and a central task force to guide and manage ResMed through the crisis Ongoing communication with suppliers and partners to ensure continuity and identify gaps Active engagement with key government officials and healthcare systems worldwide Ongoing business modeling and scenario planning Prudent cash and expense management ResMed#35Q4 FY20 financial results Diversified revenue by business & by geography OOH SaaS 12% * $ in millions, except per share amounts Revenue Non-GAAP gross margin Non-GAAP operating income* Non-GAAP EPS* 4Q20 $770.3 +9% (+10% CC) 59.9% +60 bps $243.4 +24% $1.33 +40% ResMed adjusts for the impact of the amortization of acquired intangibles, deferred revenue fair value adjustment, fair value impairment of investments, and the impact of U.S. tax reform on income tax expense from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. Masks & Other 35% Europe, Asia, and Other 36% 35 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 U.S. SaaS 12% Devices 53% Americas Sleep and Respiratory Care 52% ResMed#36Capital allocation $ in millions 4Q20 Capital Allocation Cash and cash equivalents $463.2 Debt $1,176.1 Higher priority Organic business growth Net debt $712.9 Free cash flow Free cash flow $312.3 Unused borrowing capacity $1,090.0 NOTE: Values may not calculate due to rounding During 4Q20 $52.5M invested in R&D (7% of revenue) Paid $56.5M in dividends to shareholders 36 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 * Dividends Share buybacks* Share buyback program currently suspended M&A Lower priority ResMed#37Track record of strong financial returns for shareholders Non-GAAP Revenue ($B) Operating Income ($M) Non-GAAP EPS $1.7 12% CAGR $3.0 LTM 4Q15 LTM 4Q20 16% CAGR $429 $891 LTM 4Q15 LTM 4Q20 13% CAGR $2.57 $4.76 LTM 4Q15 LTM 4Q20 Total Shareholder Return (NYSE shares as of 6/30/20): 1-yr 59% 3-yr 157% ☐ 5-yr 270% 37 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#38Striving for excellence in environmental, social, and governance processes Eliminating unnecessary waste We work to eliminate unnecessary waste in all our systems & processes, such as minimizing our use of natural resources. Minimizing pollution Product stewardship We are minimizing pollution, in particular our non-biodegradable waste to landfill. We design and develop products with reduced impact on the environment through their lifecycle. Responsible compliance We fulfill all relevant and applicable compliance obligations in the countries and communities that we operate in. Increased awareness and continual improvement We drive internal awareness of environmental impacts and monitor our performance through collaboration with others to make continual improvements Recognized by others for leading in this space: #18 on Forbes' & JUST Capital's "2019 Just 100," #1 in Healthcare Equipment and Services THE WALL STREET JOURNAL AMERICA'S MOST WS.JUST #125 on WSJ's 2019 Management Top 250 of most well-run U.S. companies for customers, employees, and investors COMPANIES Forbes 38 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#39ResMed is the global leader in connected & digital health Market Dynamics Growth & Innovation Financial Results • Underpenetrated markets in sleep and COPD • Healthcare costs continue to increase • Focus on improving patient outcomes • Value-based technology Global leader in connected health for sleep and respiratory care • Long-term growth opportunities ⚫6,000+ patents and designs •~7-8% of revenue invested in R&D • Historical revenue and profit growth . • Recurring revenue • Operating excellence program • Strong track record of disciplined capital deployment solutions Total Shareholder Return (NYSE shares as of 6/30/2020): 1-yr 59% 3-yr 157% ☐ 5-yr 270% 39 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#40In the last 12 months, we changed over 110 million lives with our digital health products and cloud-based software solutions Wednesday, January 31 myhit score 85 100 points That's a great score! You're well on your way to exproving your health 558 usage hours Adjust maksa 5.4 events per hour 601707 Jo 3 mask onvol! 4147 Our aspiration is to improve 250 million lives in 2025#41Contact Investor Relations Phone: (858) 836-5971 Email: [email protected] Website: investor.resmed.com#42APPENDIX ResMed#43Turning big data into actionable information Pioneering innovation and providing clinical evidence that support better patient outcomes and improved business efficiencies for customers AirView™ myAir 85 85 85 121% patient adherence with automated compliance coaching Labor Costs? (159% New Patient 155% Setups³ World's largest study for adherence > 128,000 patients 1. Hwang, et al., AJRCCM 2017 2. Munafo, et al. Sleep Breath 2016 1234 3. Data based on monthly patient setups and compliance rates of DME customers from February 2014 - March 2015. Historical results for this provider over the stated time Crocker, et al., Abstract CHEST 2016 124% patient adherence with patient engagement4 4. 43 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#44Improving adherence to therapy with patient monitoring and resupply ResAdhere: remote monitoring + mask resupply drive improved adherence In a study of ~100k patients with AirView cloud-connected devices... Probability on Therapy (%) 100 100% 0 Resupply group (AirView + Brightree) Control group (non-resupply) 90 Time to Drop out (days) + brightreeⓇ AirView™ 84% 66% 360 ...the likelihood of therapy termination decreased by >50% after one-year and there was a significant increase in daily PAP usage Benjafield, et al. AJRCCM 2018 (abstract) Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings. 44 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#45Big data analysis drives insights for treatment of central sleep apnea Patients with treatment-emergent central sleep apnea (CSA) are 2x more likely to terminate therapy • Opportunity to rethink conventional therapeutic options Minimize risk of therapy termination through early diagnosis • Regularly monitor patients to support adherence to treatment 100 50 Analysis of ~200k CSA patients 22% increase in adherence CMS adherence on CPAP prior to switching 62.7% CMS adherence after switching to ASV 76.6% Switching from therapy CPAP to ASV improved relative adherence by 22% Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep 45 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 AM CHEST Journal ResMed#46Opportunity to shift care from hospital to home . Healthcare costs are on the rise Combining non-invasive ventilation (NIV) with home oxygen therapy (HOT) Reduces hospitalization and mortality by 51% - - Increases time to hospital readmission or death by ~90 days JAMA® The Journal of the American Medical Association 100- 80 Admission-free Survival % 60 40 40 20 20 Admission-free survival by treatment arm over one year Adjusted hazard ratio, 0.49 (0.31-0.77); P=.002 Home Oxygen Plus Home NIV Home Oxygen Alone Combination of HOT with NIV reduced hospital readmissions by 58.3% Combination of therapies provided improved patient quality of life and saved >$50k per quality of life adjusted year 01 0 2 4 6 8 10 12 Time (months) 1 P. Murphy et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA .Published online May 21, 2017. doi: 10.1001/jama.2017.4451. 46 © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed#47Digital health solutions for inhaled COPD pharmaceuticals ● ResMed now has end-to-end solutions for Digital Health for COPD patients across stages I, II, III, IV of the disease Uses sensors with inhalers to track medication usage and provide personal feedback and insights UPSTREAM Customers include: $$ Patients$$ ● Establishes ResMed as a leading provider of COPD and asthma patient management solutions Enables digitally-enabled integration of care through the progression of the disease Health and economic outcomes Payers DOWNSTREAM Anthem gsk ✓ Boehringer Ingelheim ORION NOVARTIS Increased drug adherence and sales Pharma companies signed represent 90% of long-acting respiratory inhalation drugs Improved clinical trial speed and enhanced time to market 47 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 PBMS EXPRESS SCRIPTS Propeller Clinical insights and efficiencies Health systems Dignity Health. ($$ Patients + $$ Pharmacies Walgreens Patient Acquisition ResMed#48Propeller has demonstrated compelling clinical outcomes 1) Impact of the Propeller solution tracking inhaler usage and location SABA use over time # per day Symptom free days % Healthcare utilization Events 2.0 1.5 -50% 1.0 0.5 Uncontrolled COPD 0.0 0 Uncontrolled Asthma 75 50 50 25 +32% 0 50 100 150 200 0 50 100 150 200 Drives a decrease in medication Adherence % 36 +58% 57 40 Control Intervention Drives an improvement in adherence 48 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 Drives an improvement in QOL QoL: Rescue Inhaler use per day # times used 1.5 1.0 -75% 0.5 0.0 1 180 Drives an improvement in QOL -25% 79 Before 59 After Drives a reduction in healthcare utilization Acute care utilization Events per 100 patient years 13 Pre-enrollment Post-enrollment 12 6 5 365 ED + Hosp. ED 2 0 Hosp. Drives a reduction in healthcare utilization ResMed#49Propeller's digital medicine platform drives reduced healthcare utilization ◉Cleveland Clinic Study Overview: Propeller Cleveland Clinic enrolled people into Propeller as part of their routine clinical care and monitored them for at least one year. Providers monitored drug use and adherence to inhaled controller medications, providing follow-up as needed. Population: COPD patients with ≥1 utilization (Emergency Department ("ED") visit or hospitalization) in prior 12 months N = 39; mean age: 69 years, 51% male, 69% African American, mean FEV11 predicted: 47.2%, mean CAT: 192 Numbe of Hospitalizations and ED visits per person per year LO 4 M N Results: 12 months prior p = 0.06 4.7 ± 4.1 12 months during monitoring 3.4 + 2.6 3.4 ± 3.2 2.2 ± 2.3 1. FEV1 - Forced Expiratory Volume in 1 second - the volume of air that can be forcibly blown out in the first second after full inspiration. Values between 80% and 120% are considered normal 2. CAT = COPD Assessment Test – an eight-item questionnaire designed to quantify the impact of COPD symptoms on a patient's health status.. Scored between 0-40, <10 Low, 10-20 Medium, 21-30 High, >30 Very high Alshabani K, et al. Electronic inhaler monitoring and healthcare utilization in chronic obstructive pulmonary disease. J Telemed Telecare. 2019 49 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 All-cause COPD Healthcare Utilization ResMed#5050 History of successful SaaS acquisitions Company UMB AN JAYSEC TECHNOLOGIES Location Halifax, NS Canada Date Aug 2012 Key Product Status U-Sleep Integrated into AirView. Knoxville, TN Feb 2015 GoJaysec Rebranded as GoScripts. CareTouch brightree Denver, CO Jul 2015 Care Touch 360 Rebranded as ResMed ReSupply. Lawrenceville, GA Feb 2016 Brightree Core Operating as a wholly-owned subsidiary. by ResMed conduittechnology AllCall Connect Girard, PA Jun 2017 MyForms Integrated into Brightree. Joliet, IL Jul 2017 Brightree ConnectPRO Integrated into Brightree. HEALTHCARE first Springfield, MO Jul 2018 by ResMed first HOMECARE Software (EHR) Integrated with Brightree and MatrixCare. MatrixCare Bloomington, MN Nov 2018 MatrixCare One Operating as a wholly owned subsidiary. by ResMed Apacheta Media, PA Dec 2018 Mobile Business Solutions SNAPWOR Brentwood, TN Jan 2020 A division of Brightree Apacheta ACE (a mobile enterprise application platform) SNAP SNAP+RPM Operating as a part of Brightree, with an independent brand Operating as a part of Brightree, with an independent brand. © 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed